CERO THERAPEUTICS HOLDINGS, INC. Quarterly Debt-to-equity in % from Q2 2022 to Q3 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Cero Therapeutics Holdings, Inc. quarterly Debt-to-equity history and growth rate from Q2 2022 to Q3 2024.
  • Cero Therapeutics Holdings, Inc. Debt-to-equity for the quarter ending September 30, 2024 was -73.1 %, a 54.6% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q3 2024 -73.1 +87.8 +54.6% Sep 30, 2024
Q2 2024 -67.3 +102 +60.2% Jun 30, 2024
Q1 2024 -62.4 +118 +65.4% Mar 31, 2024
Q4 2023 -55.8 +133 +70.5% Dec 31, 2023
Q3 2023 -161 -45.5 -39.5% Sep 30, 2023
Q2 2023 -169 -50.6 -42.8% Jun 30, 2023
Q1 2023 -180 Mar 31, 2023
Q4 2022 -189 Dec 31, 2022
Q3 2022 -115 Sep 30, 2022
Q2 2022 -118 Jun 30, 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.